Actuate Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Actuate Therapeutics, Inc. (ACTU) reported Basic Shares Outstanding (Weighted Average) of 23.87 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-14
- Actuate Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 23.87M shares, a 21.51% increase year-over-year.
- Actuate Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 23.54M shares, a 20.72% increase year-over-year.
- Actuate Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 23.53M shares, a 20.35% increase year-over-year.
- Actuate Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 21.39M shares, a 98.60% increase year-over-year.
- Actuate Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 21.02M shares, a 151.07% increase from fiscal 2024.
- Actuate Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 8.37M shares, a 483.48% increase from fiscal 2023.
- Actuate Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 1.43M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 23.87M shares 10-Q · filed 2026-08-14 | 23.71M shares 10-Q · filed 2026-08-14 | 23.65M shares derived: average of 3 quarters · filed 2026-08-14 | 23.08M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 23.54M shares 10-Q · filed 2026-05-14 | 23.53M shares derived: average of 2 quarters · filed 2026-05-14 | 22.82M shares derived: average of 3 quarters · filed 2026-05-14 | 22.03M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | 23.53M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 22.46M shares derived: average of 2 quarters · filed 2026-03-26 | 21.52M shares derived: average of 3 quarters · filed 2026-08-14 | 21.02M shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 21.39M shares 10-Q · filed 2025-11-13 | 20.52M shares derived: average of 2 quarters · filed 2026-08-14 | 20.19M shares 10-Q · filed 2025-11-13 | 20.02M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | 19.65M shares 10-Q · filed 2026-08-14 | 19.57M shares 10-Q · filed 2026-08-14 | 19.56M shares derived: average of 3 quarters · filed 2026-08-14 | 17.37M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | 19.50M shares 10-Q · filed 2026-05-14 | 19.52M shares derived: average of 2 quarters · filed 2026-05-14 | 16.61M shares derived: average of 3 quarters · filed 2026-05-14 | 12.85M shares derived: average of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | 19.55M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 15.16M shares derived: average of 2 quarters · filed 2026-03-26 | 10.63M shares derived: average of 3 quarters · filed 2026-03-26 | 8.37M shares 10-K · filed 2026-03-26 |
| 2024-09-30 | 10.77M shares 10-Q · filed 2025-11-13 | 6.17M shares derived: average of 2 quarters · filed 2025-11-13 | 4.65M shares 10-Q · filed 2025-11-13 | 3.84M shares derived: average of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | 1.57M shares 10-Q · filed 2025-08-14 | 1.55M shares 10-Q · filed 2025-08-14 | 1.53M shares derived: average of 3 quarters · filed 2025-08-14 | 1.52M shares derived: average of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | 1.54M shares 10-Q · filed 2025-05-15 | 1.52M shares derived: average of 2 quarters · filed 2025-05-15 | 1.50M shares derived: average of 3 quarters · filed 2025-05-15 | 1.48M shares derived: average of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | 1.50M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 1.49M shares derived: average of 2 quarters · filed 2025-03-13 | 1.47M shares derived: average of 3 quarters · filed 2025-03-13 | 1.43M shares 10-K · filed 2025-03-13 |
| 2023-09-30 | 1.47M shares 10-Q · filed 2024-11-13 | 1.45M shares derived: average of 2 quarters · filed 2024-11-13 | 1.41M shares 10-Q · filed 2024-11-13 | |
| 2023-06-30 | 1.42M shares 10-Q · filed 2024-09-24 | 1.38M shares 10-Q · filed 2024-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |